Failure of Teriparatide in Treatment of Bone Complications of Adult Hypophosphatasia.

10:00 EDT 20th September 2014 | BioPortfolio

Summary of "Failure of Teriparatide in Treatment of Bone Complications of Adult Hypophosphatasia."

No Summary Available

Affiliation

Service de Rhumatologie, CHU Purpan, 1 place du Dr Baylac, TSA 40031, 30159, Toulouse Cedex 09, France, laroche.m@chu-toulouse.fr.

Journal Details

This article was published in the following journal.

Name: Calcified tissue international
ISSN: 1432-0827
Pages:

Links

PubMed Articles [27386 Associated PubMed Articles listed on BioPortfolio]

New Development in Osteoporosis Treatment. Once-weekly teriparatide treatment on osteoporosis.

Teriparatide (human PTH 1-34) transiently stimulate both bone formation and bone resorption and subsequently bone formation markers increased. The changes in bone turnover markers 24 h after each inje...

Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series.

Introduction. Bone disease is a common complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of teriparatide, recombinant human parathyroid hormone, to treat C...

New Development in Osteoporosis Treatment. Daily subcutaneous injection of teriparatide : the progress and current issues.

Daily subcutaneous injection of teriparatide, which consists of 34 amino acids of N-terminal of parathyroid hormone, has been investigated as a therapy for osteoporosis. It has been used since 2010 in...

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.

The results of the present study, involving analysis of biopsies from patients who received teriparatide for 2 years and were previously either treatment-naïve or on long-term alendronate therapy, s...

Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once-weekly teriparatide.

Abstract Objective We aimed to evaluate the surrogacy of bone mineral density and bone turnover markers for incident vertebral fracture using data from 237 patients treated with once-weekly 56.5 µg t...

Clinical Trials [4763 Associated Clinical Trials listed on BioPortfolio]

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures. Teriparatide [PTH(1-34)], which is FDA approved...

Safety Study of ENB-0040 in Severely Affected Infants With Hypophosphatasia (HPP)

This Clinical Trial is being conducted to study Hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to h...

Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein (ENB-0040) in Adults With Hypophosphatasia (HPP)

This Clinical Trial is being conducted to study Hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to ha...

A Study for the Transdermal Application of Teriparatide

The primary purpose of this study is to help answer the following research questions: 1. How teriparatide given using a skin patch (transferred through the skin using the ViaDerm T...

Safety and Efficacy Study of ENB-0040 in Adolescents and Adults With Hypophosphatasia (HPP)

This clinical trial is being conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to h...

Medical and Biotech [MESH] Definitions

A genetic metabolic disorder resulting from serum and bone alkaline phosphatase deficiency leading to hypercalcemia, ethanolamine phosphatemia, and ethanolamine phosphaturia. Clinical manifestations include severe skeletal defects resembling vitamin D-resistant rickets, failure of the calvarium to calcify, dyspnea, cyanosis, vomiting, constipation, renal calcinosis, failure to thrive, disorders of movement, beading of the costochondral junction, and rachitic bone changes. (From Dorland, 27th ed)

The continuous turnover of bone matrix and mineral that involves first, an increase in resorption (osteoclastic activity) and later, reactive bone formation (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium homeostasis. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.

Complications that affect patients during surgery. They may or may not be associated with the disease for which the surgery is done, or within the same surgical procedure.

The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.

Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.

Search BioPortfolio:
Loading